Methicillin-resistant Staphylococcus aureus: A pervasive pathogen highlights the need for new antimicrobial development

Yale Journal of Biology and Medicine

Volumn 83, Issue 4, 2010, Pages 223-233

  Morell, Emily A ^a   Balkin, Daniel M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

10 '20 initiative; Antibiotic development; Antibiotic resistance; Community associated MRSA; Methicillin resistant; Penicillin; Penicillin binding proteins; Staphylococcus aureus; Virulence factors

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; MEMBRANE PROTEIN; METICILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BINDING AFFINITY; CLINICAL FEATURE; COMMUNITY ASSOCIATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG PROTEIN BINDING; DRUG STRUCTURE; HOSPITAL INFECTION; HUMAN; IMMUNE SYSTEM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; PIPELINE; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLIN-BINDING PROTEINS; VIRULENCE FACTORS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 79953132492     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001;32:675- 85.
2. Gorwitz RJ, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008;197:1226-34.
3. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3:948-58.
4. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:752-60.
5. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-41.
6. Patti JM, et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol. 1994;48:585-617.
7. Sritharan M, Sritharan V. Emerging problems in the management of infectious diseases: the biofilms. Indian J Med Microbiol. 2004;22:140- 2.
8. Geoghegan JA, et al. The Role of Surface Protein SasG in Biofilm Formation by Staphylococcus aureus. J Bacteriol. 2010;192(21):5663-73.
9. Cirioni O, et al. Daptomycin and Rifampin Alone and in Combination Prevent Vascular Graft Biofilm Formation and Emergence of Antibiotic Resistance in a Subcutaneous Rat Pouch Model of Staphylococcal Infection. Eur J Vasc Endovasc Surg. Forthcoming 2010.
10. Schwarz-Linek U, et al. The molecular basis of fibronectin-mediated bacterial adherence to host cells. Mol Microbiol. 2004;52:631-41.
11. Tang YW, Stratton CW. Staphylococcus aureus: An old pathogen with new weapons. Clin Lab Med. 2010;30:179-208.
12. Fowler T, et al. Cellular invasion by Staphylococcus aureus involves a fibronectin bridge between the bacterial fibronectin-binding MSCRAMMs and host cell beta1 integrins. Eur J Cell Biol. 2000;79:672-9.
13. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981;20:2361-70.
14. de Haas CJ, et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med. 2004;199:687- 95.
15. Gladstone GP, Van Heyningen WE. Staphylococcal leucocidins. Br J Exp Pathol. 1957;38:123-37.
16. Gordon RJ, Lowy FD. Pathogenesis of methicillin- resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(Suppl 5):S350-9.
17. Todd J, et al. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;2:1116-8.
18. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-32.
19. Gilbert RJ, et al. Serological detection of enterotoxin in foods implicated in staphylococcal food poisoning. J Hyg (Lond). 1972;70:755-62.
20. Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents. 2009;34(Suppl 1):S2-7.
21. Napolitano LM. Severe soft tissue infections. Infect Dis Clin North Am. 2009;23:571-91.
22. Gauduchon V, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis. 2004;189:346-53.
23. Yanagisawa C, et al. Neutralization of staphylococcal exotoxins in vitro by humanorigin intravenous immunoglobulin. J Infect Chemother. 2007;13:368-72.
24. Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog. 2002;85:57-72.
25. Wu SW, et al. Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus. J Bacteriol. 2001;183:2417-24.
26. Katayama Y, et al. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2000;44:1549-55.
27. Kreiswirth B, et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science. 1993;259:227-30.
28. Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to beta-lactams. Antimicrob Agents Chemother. 1993;37:2045- 53.
29. Landau R, et al. Pharmaceutical innovation: revolutionizing human health. Philadelphia: Chemical Heritage Press; 1999.
30. Barber M. Methicillin-resistant staphylococci. J Clin Pathol. 1961;14:385-93.
31. Barrett FF, et al. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med. 1968;279:441-8.
32. Lim D, Strynadka NC. Structural basis for the beta lactam resistance of PBP2a from methicillin- resistant Staphylococcus aureus. Nat Struct Biol. 2002;9:870-6.
33. Guignard B, et al. Beta-lactams against methicillin- resistant Staphylococcus aureus. Curr Opin Pharmacol. 2005;5:479-89.
34. Sheretz RJ, et al. A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann Intern Med. 1996;124:539-47.
35. Henderson DK. Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms. Am J Med. 2006;119:S45-52, discussion S62-70.
36. Klevens RM, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006;42:389-91.
37. Klein E, et al. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13:1840-6.
38. Klevens RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-71.
39. Deleo FR, et al. Community-associated methicillin- resistant Staphylococcus aureus. Lancet. 2010;375:1557-68.
40. Kallen AJ, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA. 2010;304:641-8.
41. Tacconelli E. Methicillin-resistant Staphylococcus aureus: source control and surveillance organization. Clin Microbiol Infect. 2009;15(Suppl 7):31-8.
42. Burton DC, et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA. 2009;301:727-36.
43. Harris SR, et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science. 2010;327:469-74.
44. Udo EE, et al. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect. 1993;25:97-108.
45. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus- Minnesota and North Dakota, 1997- 1999. JAMA. 1999;282:1123-5.
46. Prevost G, et al. Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun. 1995;63:4121-9.
47. Gorwitz RJ, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf.
48. Nathwani D, et al. Guidelines for UK practice for the diagnosis and management of methicillin- resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61:976-94.
49. Infectious Diseases Society of America [Internet]. Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates... A Public Health Crisis Brews. 2004. Available at: http://www.idsociety.org/10x20.htm.
50. Spellberg B, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38:1279-86.
51. DiMasi JA, et al. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85.
52. Tollman P, et al. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry. Boston: Boston Consulting Group; 2001.
53. Spellberg B, et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:155-64.
54. Infectious Diseases Society of America. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50:1081-3.
55. Charest MG, et al. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science. 2005;308:395-8.
56. Sun C, et al. A robust platform for the synthesis of new tetracycline antibiotics. J Am Chem Soc. 2008;130:17913-27.
57. Drugs.com [Internet]. Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC. 2010. Available at: http://www.drugs.com/clinical_trials/tetraphase-present-extensive-data-novel-broad-spectrum-antibiotic-tp-434-icaac-10049.html.
58. Tu D, et al. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005;121:257-70.
59. Nobelprize.org [Internet]. The Nobel Prize in Chemistry 2009 - Press Release. [cited 2010 Oct 24]. Available at: http://nobelprize.org/nobel_prizes/chemistry/laureates/2009/press.html.
60. Rib-X.com [Internet]. Rib-X Pharmaceuticals Presents Data Supporting Delafloxacin as a Potential Best-in-class Fluoroquinolone at ICAAC - Delafloxacin's Unique Chemical Structure Leads to Increased Potency and Efficacy at the Site of Infection. 2010. [cited 2010 Oct 24]. Available at: http://www.ribx.com/news_and_events/press_releases.